# HK inno.N Corporation clinical trials: 104 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 104 trials with HK inno.N Corporation as lead sponsor, 15 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by HK inno.N Corporation: 104 rows for $5.20, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/hk-inno-n-corporation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 104
- Recruiting or not yet: 15
- Read on: November 19, 2026

## Trials

The 25 newest of 104, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07930260 | Efficacy and Safety of Kabalin Cap.(Pregabalin) in Patients With Neuropathic Pain | HK inno.N Corporation | Observational | Recruiting | Peripheral or Central Neuropathic Pain | 5,217 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930260) |
| November 12, 2026 | NCT07930247 | Blood Pressure Control and Safety of Ex-one or Ex-one Plus in Essential Hypertension | HK inno.N Corporation | Observational | Recruiting | Essential Hypertension | 7,525 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930247) |
| November 10, 2026 | NCT07930169 | Observational Study to Evaluate the Safety and Efficacy of Kremezin IDT/Fine Gran in Progressive Chronic Kidney Disease Patients. | HK inno.N Corporation | Observational | Recruiting | Chronic Kidney Disease | 3,125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930169) |
| November 9, 2026 | NCT07924345 | Observational Study to Evaluate Achieving LDL-cholesterol Target Level to Treat With Rovazet Tab. With Dyslipidemia Patients | HK inno.N Corporation | Observational | Recruiting | Dyslipidemia | 6,713 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924345) |
| November 6, 2026 | NCT07920679 | Efficacy and Safety of K-CAB(Tegoprazan) 25 mg as Maintenance Therapy Following the Treatment of GERD | HK inno.N Corporation | Observational | Recruiting | Maintenance Therapy Following Treatment for Gastroesophageal Reflux Disease(GERD) | 12,868 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920679) |
| October 1, 2026 | NCT07853248 | Tegoprazan-Aspirin Drug Interaction in Healthy Adult Male Volunteers | HK inno.N Corporation | Phase 1 | Not yet recruiting | Healthy Adult Male | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07853248) |
| September 17, 2026 | NCT07826455 | A Study to Evaluate Tegoprazan as a Diagnostic Tool for GERD | HK inno.N Corporation | Phase 4 | Not yet recruiting | GERD (Gastroesophageal Reflux Disease) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07826455) |
| July 1, 2026 | NCT07678177 | An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients | HK inno.N Corporation | Observational | Recruiting | GERD (Gastroesophageal Reflux Disease) | 5,384 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678177) |
| June 25, 2026 | NCT07668180 | A Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia | HK inno.N Corporation | Phase 2 | Not yet recruiting | Sarcopenia in Elderly | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668180) |
| December 31, 2025 | NCT07311811 | A Study to Evaluate the Pharmacokinetics and Safety of IN-M00007 and IN-R00007 in Healthy Adult Volunteers | HK inno.N Corporation | Phase 1 | Not yet recruiting | Healthy Volunteers | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07311811) |
| December 29, 2025 | NCT07308184 | Bridge Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Patients With T2DM Inadequately Controlled by Diet and Exercise... | HK inno.N Corporation | Phase 3 | Not yet recruiting | Diabetes (DM), Diabetes Mellitus Type 2 | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07308184) |
| December 11, 2025 | NCT07277712 | A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult Volunteers | HK inno.N Corporation | Phase 1 | Not yet recruiting | Healthy Volunteer | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07277712) |
| September 25, 2025 | NCT07192263 | Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus | HK inno.N Corporation | Phase 3 | Not yet recruiting | Obesity &Amp; Overweight | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07192263) |
| July 18, 2025 | NCT07073677 | A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients | HK inno.N Corporation | Phase 2 | Recruiting | Mild to Moderate Atopic Dermatitis | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07073677) |
| December 17, 2024 | NCT06736912 | This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in... | HK inno.N Corporation | Phase 1 | Not yet recruiting | Chronic Idiopathic Constipation | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06736912) |
| December 10, 2024 | NCT06725355 | To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adult Volunteers | HK inno.N Corporation | Phase 1 | Active not recruiting | Non-valvular Atrial Fibrillation (NVAF) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06725355) |
| April 29, 2024 | NCT06389552 | Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients | HK inno.N Corporation | Observational | Active not recruiting | Adjuvant Chemotherapy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06389552) |
| March 27, 2024 | NCT06332638 | PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects | HK inno.N Corporation | Phase 1 | Unknown | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06332638) |
| December 11, 2023 | NCT06164834 | Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects | HK inno.N Corporation | Phase 1 | Unknown | Healthy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06164834) |
| July 6, 2023 | NCT05933031 | Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients | HK inno.N Corporation | Phase 2 | Unknown | Helicobacter Pylori Infection | 381 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05933031) |
| February 15, 2023 | NCT05729074 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild... | HK inno.N Corporation | Phase 1 | Completed | Mild to Moderate Atopic Dermatitis | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05729074) |
| February 10, 2023 | NCT05723510 | PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers | HK inno.N Corporation | Phase 1 | Completed | Healthy | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05723510) |
| January 27, 2023 | NCT05701540 | A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn | HK inno.N Corporation | Phase 4 | Unknown | Gastroesophageal Reflux Disease | 338 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05701540) |
| April 29, 2022 | NCT05353010 | A Study to Evaluate Effect of IN-A001 on Pharmacokinetics of Tacrolimus in Healthy Volunteers | HK inno.N Corporation | Phase 1 | Unknown | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05353010) |
| April 20, 2022 | NCT05337228 | Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Peri Inj. Compared With RPN301 | HK inno.N Corporation | Phase 3 | Completed | Parenteral Nutrition | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05337228) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 64 |
| Phase 2 | 6 |
| Phase 3 | 18 |
| Phase 4 | 9 |
| Observational | 7 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 64 |
| Unknown | 22 |
| Not yet recruiting | 8 |
| Recruiting | 7 |
| Active not recruiting | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypertension | 7 |
| Gastroesophageal Reflux | 5 |
| Diabetes Mellitus | 5 |
| Hyperlipidemias | 4 |
| Essential Hypertension | 4 |
| Hyperphagia | 2 |
| Hand, Foot and Mouth Disease | 2 |
| Obesity | 1 |
| Overweight | 1 |
| Neuralgia | 1 |
| Digestive System Diseases | 1 |
| Schizophrenia | 1 |
| Psychotic Disorders | 1 |
| Renal Insufficiency, Chronic | 1 |
| COVID-19 | 1 |
| Rhinitis, Allergic, Perennial | 1 |
| Dyslipidemias | 1 |
| Stomach Ulcer | 1 |
| Non-Erosive Reflux Disease | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Coronary Artery Disease | 1 |
| Liver Cirrhosis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Oral and maxillofacial surgery practices in the United States](https://specstream.ai/data/businesses/oral-and-maxillofacial-surgery-practices/united-states)
- [Marble and granite professional companies in the United States](https://specstream.ai/data/businesses/marble-and-granite-professional-companies/united-states)
- [Insulation contractors in the United States](https://specstream.ai/data/businesses/insulation-contractors/united-states)
- [Granite suppliers in the United States](https://specstream.ai/data/businesses/granite-suppliers/united-states)
- [Executive search firms in the United States](https://specstream.ai/data/businesses/executive-search-firms/united-states)
- [Dialysis clinics in the United States](https://specstream.ai/data/businesses/dialysis-clinics/united-states)
